Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
01:54pm, Thursday, 06'th Nov 2025
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced t
Coherus Oncology (CHRS) to Release Quarterly Earnings on Thursday
02:45am, Tuesday, 04'th Nov 2025
Coherus Oncology (NASDAQ: CHRS - Get Free Report) is projected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
08:30am, Thursday, 30'th Oct 2025
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thu
Coherus Oncology to Participate in Upcoming Investor Conferences
08:30am, Thursday, 23'rd Oct 2025
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conference
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
09:05am, Friday, 03'rd Oct 2025
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolyt
Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript
05:02pm, Wednesday, 01'st Oct 2025
Coherus Oncology, Inc. (NASDAQ:CHRS ) UBS Virtual Oncology Day October 1, 2025 1:00 PM EDT Company Participants Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Den
Coherus Oncology: Five Readouts Or More Possible In 2026
10:43am, Wednesday, 01'st Oct 2025
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatoce
Coherus Oncology: On The Shaping Up
04:55pm, Monday, 25'th Aug 2025
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited
Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript
11:35am, Saturday, 09'th Aug 2025
Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.
Coherus (CHRS) Q2 Revenue Jumps 10%
09:37pm, Thursday, 07'th Aug 2025
Coherus (CHRS) Q2 Revenue Jumps 10%
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
07:26pm, Thursday, 07'th Aug 2025
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.14 per share a year ago.
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
04:41pm, Thursday, 07'th Aug 2025
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and market
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
04:45pm, Thursday, 31'st Jul 2025
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results
Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript
10:46pm, Monday, 12'th May 2025
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer T
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
06:30pm, Monday, 12'th May 2025
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.
